India is renowned for its rich ancient medicinal heritage and the compilation of that knowledge in Ayurveda, has long been regarded as a source of medicinal knowledge. The Charaka Samhita together with the Sushruta Samhita, are the two important foundational texts or grantha of Ayurveda that have survived till date. Despite being the largest manufacturer and supplier of generic medicines globally in the present day, the Indian pharmaceutical industry in the 21st century has been plagued by significant concerns arising from recurring incidents of manufacturing irregularities. From legal issues faced by prominent companies to tragic cases of deaths and product recalls, the industry's integrity and quality standards have come under scrutiny.
The pharmaceutical industry in India has witnessed several high-profile incidents that have raised serious concerns. First such case came to light in 2013 when Ranbaxy Laboratories Ltd., one of India's leading pharmaceutical companies, pleaded guilty to felony charges related to the production and distribution of adulterated drugs in the United States. December 2022 marked an import US FDA imposing an import alert on Sun Pharmaceuticals, India's largest revenue-generating drug manufacturer, when its capsule samples failed to meet dissolution specifications.
Among the recurring incidents of irregularities in manufacturing, two big cases in 2022 made news headlines across the world. The first incident involved Marion Biotech, a pharmaceutical company that came under scrutiny after the tragic death of 18 children in Uzbekistan.The second incident involved Maiden Pharmaceuticals, another Indian pharmaceutical company, whose cough syrups were implicated in the deaths of 66 children in Gambia.
The Indian pharmaceutical industry has witnessed heartbreaking incidents where the lives of patients, especially children, were lost due to substandard drugs. Similar incident was reported in January 2020 when 12 children in Jammu lost their lives after consuming contaminated medicine manufactured by Digital Vision, a firm based in Himachal Pradesh.
More recently, in February 2023, Global Pharma Healthcare had to recall an entire batch of exported eye drops after they were linked to cases of vision loss in the United States. These incidents underscore the urgent need for stringent quality assurance measures to protect public health. Another distressing incident reported recently in Shri Lanka, where a hospitalized patient tragically lost life after being administered the Indian-manufactured anesthetic Bupivacaine, this was second such case two months after a pregnant woman passed away at the same hospital after being given an Indian anaesthetic drug. Gujarat-based Savorite Pharmaceuticals (Pvt) Ltd. and Chennai-based Kausikh Therapeutics were named as respondents in the case.
The Indian pharmaceutical industry stands at a crucial crossroads. While these incidents have exposed the vulnerabilities within the system, they have also served as catalysts for change. As the Indian pharmaceutical industry grapples with these challenges, it is crucial to foster a culture of accountability, transparency, and continuous improvement. Efforts must be made to reinforce regulatory oversight, implement robust quality assurance protocols, and prioritize patient safety above all else.